Quick Summary
Retatrutide is a triple agonist peptide (GLP-1, GIP, Glucagon) under active clinical investigation.
Preclinical and Phase II trial data show dose-dependent fat loss, metabolic, and appetite-regulation effects.
Titration protocols start at 1mg/week and escalate gradually — skipping steps increases adverse event risk.
Peptides Lab UK offers HPLC-verified, COA-confirmed Retatrutide in lyophilised vials for…
